Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483244 | 0.82 | TDP1 (0.48) | TDP1CYP1A2PIK3CDKDM4ESMN1; SMN2 | |
| SCHEMBL447068 | 0.81 | TDP1 (0.52) | TDP1CYP1A2SMN1; SMN2KMT2AHTT | |
| SCHEMBL14407779 | 0.79 | CYP1A2 (0.77) | TDP1CYP1A2PIK3CDKDM4ESMN1; SMN2 | |
| SCHEMBL860793 | 0.79 | CYP1A2 (0.77) | TDP1CYP1A2PIK3CDKDM4ESMN1; SMN2 | |
| SCHEMBL37407 | 0.79 | — | — | |
| SCHEMBL196593 | 0.78 | TDP1 (0.54) | TDP1CYP1A2PIK3CDKDM4ESMN1; SMN2 | |
| SCHEMBL6042558 | 0.78 | CYP1A2 (0.54) | TDP1CYP1A2PIK3CDKDM4ESMN1; SMN2 | |
| SCHEMBL6042554 | 0.78 | TDP1 (0.54) | TDP1CYP1A2PIK3CDKDM4ESMN1; SMN2 | |
| SCHEMBL772617 | 0.77 | HSD11B1 (0.51) | KDM4EALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL206420 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102123763-B | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use thereof | XENOPORT, INC. (US) | 2014-10-08 | — | — | CN | claimed |
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | claimed |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| WO-2014031901-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| JP-2012500285-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | claimed |
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | claimed |
| US-6844366-B2 | Sulfonamide hydroxamates | SYNTEX (U.S.A.) LLC (US) | 2005-01-18 | — | — | US | claimed |
| WO-2004004727-A1 | 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | disclosed |
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-10463642-B2 | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate | RAJASEKHAR VIJAYKUMAR (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2000037436-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| EP-0515420-B1 | NITRIC ACID ESTERS OF CYCLOHEXANOL DERIVATIVES | BOEHRINGER MANNHEIM GMBH (DE) | 1996-06-12 | — | — | EP | disclosed |
| US-5411989-A | Cardiovascular disorders | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-05-02 | — | — | US | disclosed |
| EP-0515420-A1 | NITRIC ACID ESTERS OF CYCLOHEXANOL DERIVATIVES. | BOEHRINGER MANNHEIM GMBH (DE) | 1992-12-02 | — | — | EP | disclosed |
| WO-1991012230-A1 | NITRIC ACID ESTERS OF CYCLOHEXANOL DERIVATIVES | BOEHRINGER MANNHEIM GMBH (DE) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | FH, FAH, ALDOA | TDP1 2053/4885CYP1A2 182/4885PIK3CD 3814/4885 |
| US-10463642-B2 | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate | FH, HMGCR, HPGD | TDP1 1742/4885CYP1A2 991/4885PIK3CD 3437/4885 |
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | CASP3, BAX, BAD | TDP1 874/4885CYP1A2 1053/4885PIK3CD 843/4885 |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | FH, FAH, DHFR | TDP1 2365/4885CYP1A2 758/4885PIK3CD 4243/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | TDP1 1050/4885CYP1A2 474/4885PIK3CD 2576/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | TDP1 2044/4885CYP1A2 260/4885PIK3CD 1650/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | TDP1 2053/4885CYP1A2 182/4885PIK3CD 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.